Conditions: Schizophrenia Schizoaffective Disorder Bipolar I Disorder Metabolic Syndrome
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 64
Healthy volunteers: no

Brief summary:
The purpose of this study was to determine whether patients with schizophrenia, schizoaffective disorder, or bipolar I disorder who also have metabolic syndrome have a larger decrease in fasting non-high density lipoprotein (non-HDL) cholesterol levels with aripiprazole than with their current atypical antipsychotic treatment (olanzapine, risperidone, or quetiapine).

Detailed description:

Arms:
arm 1: None arm 2: None

Interventions: intervention 1: Aripiprazole intervention 2: Oanzapine, risperidone, or quetiapine
Intervention descriptions: intervention 1: Aripiprazole administered orally as tablets, 5 mg once daily (QD) in Week 1; 10 mg QD in Week 2. Flexible dosing allowed after Week 2, adjusted in 5-mg increments every 7 days within a range of 10 to 30 mg daily, for 16 weeks intervention 2: Oanzapine, risperidone, or quetiapine administered orally as tablets at prior dosage for 16 weeks

Protocol document: